

Review of: "Advancements in the Detection and Treatment of Rare ALK Fusion Mutations in Hepatocellular Carcinoma: A Case Report and Literature Review"

Aydın Demiray¹

¹ Pamukkale University

Potential competing interests: No potential competing interests to declare. Non

The article is certainly significant for the treatment of HCC patients. I just wanted to share that I have some reservations about the article.

For instance, the radiological and pathological findings of the patients are missing, and the average PFS duration of metastatic HCC patients is not provided. It would also be helpful to mention the contribution of ALK inhibitors to the treatment. Additionally, the last three paragraphs of the discussion section lack references.